Most of the confident claims you see online about peptides trace back to two or three papers, often misread, occasionally cherry-picked, and sometimes pre-clinical work in rodents repackaged as human dosing guidance. A short checklist for separating signal from confidence theater. This framework applies to evaluating claims in research-grade specifications, lab reports, and any marketing material citing peptide studies.
Check the species, then the tissue
The first thing to note about any peptide paper is what system it was run in. In vitro work in a cell culture tells you a compound can bind a receptor. It does not tell you it will reach that receptor after subcutaneous injection. Rodent work is more predictive, but route of administration, body composition, and half-life all differ — a compound that works IP in a mouse may not produce the same pharmacokinetic curve subcutaneously in a human.
Human data trumps everything, but there is less of it than the internet suggests. If the human data is a 12-person crossover, treat it as a hypothesis generator, not a protocol.
Read the dose conversions
Allometric scaling — converting from mouse mg/kg to human equivalent — is not optional. Papers doing it wrong are common. Look for the Reagan-Shaw formula (or a similar body-surface-area correction). If the paper jumps directly from mouse mg/kg to human mg/kg without scaling, the dose estimates in the abstract are likely 10x too high.
Separate mechanism from outcome
A peptide paper will usually have a mechanism section (it binds this receptor, activates this pathway) and an outcome section (subjects lost weight, recovered faster, slept better). Mechanism claims are easier to verify but don't guarantee the outcome. Outcome claims matter more but are noisier.
If a compound has a strong mechanism story and weak outcome data, you're looking at an early-stage hypothesis. If it has strong outcome data but a fuzzy mechanism, the effect is probably real but the reason may be different from what the authors proposed.